AvalehtPTKFY • OTCMKTS
add
PT Kalbe Farma Unsponsored Indonesia ADR
Viimane sulgemishind
19,94 $
Aasta vahemik
16,38 $ - 23,73 $
Turuväärtus
71,26 trln IDR
Keskmine maht
1,13 tuh
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (IDR) | sept 2024info | Y/Y muutus |
|---|---|---|
Käive | 7,91 trln | 7,16% |
Põhitegevusega seonduv kulu | 2,29 trln | 15,55% |
Puhastulu | 573,28 mld | 6,97% |
Puhaskasumimarginaal | 7,25 | −0,14% |
Puhaskasum aktsia kohta | 12,41 | 7,73% |
EBITDA | 874,81 mld | 1,14% |
Tõhus maksumäär | 23,01% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (IDR) | sept 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 4,32 trln | 45,45% |
Kogu vara | 28,75 trln | 5,78% |
Kõik kohustused | 4,84 trln | 0,67% |
Kogu omakapital | 23,91 trln | — |
Emiteeritud aktsiate arv | 46,15 mld | — |
Hinna ja väärtuse suhe P/B | 0,04 | — |
Varade tasuvus | 6,15% | — |
Kapitali tasuvus | 7,16% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (IDR) | sept 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | 573,28 mld | 6,97% |
Põhitegevuse rahakäive | 1,16 trln | 22,56% |
Investeeringute raha | −176,64 mld | 33,78% |
Finantseerimise raha | −421,11 mld | 51,91% |
Raha ja raha ekvivalentide muutus | 481,86 mld | 1 978,42% |
Tasuta rahavoog | 752,00 mld | 13,84% |
Teave
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
Asutatud
10. sept 1966
Veebisait
Töötajate arv
12 924
